Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

igates its exposure to credit risk by restricting its

portfolio to investment grade securities with short term maturities and

by monitoring the credit risk and credit standing of counterparties.

Interest rate risk

Interest rate risk is the risk that future cash flows of a financial

instrument will fluctuate because of changes in market interest rates.

The Company is exposed to interest rate risk through its cash and cash

equivalents and its portfolio of short-term investments. The Company

mitigates this risk through its investment policy that only allows

investment of its excess cash resources in investment grade vehicles

while matching maturities with the Company's operational requirements.

Fluctuations in market rates of interest do not have a significant impact

on the Company's results of operations due to the short term to maturity

of the investments held.

Currency risk

Currency risk is the risk that future cash flows of a financial

instrument will fluctuate because of changes in foreign exchange rates.

The Company is exposed to currency risk from the purchase of goods and

services primarily in the U.S. and the U.K. The Company mitigates its

foreign exchange risk through the purchase of foreign currencies in

sufficient amounts to settle its foreign accounts payable.

Balances in foreign currencies at March 31, 2008 are as follows:


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Second generation biofuels are a viable solution ... However, as natural gas is very cheap, this is affecting ... as valuable as they could be in comparison to natural ... has made it difficult for renewable energy developers to get ... ground. For these reasons, certain companies have shifted their focused ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today a ... to provide access to Nanosyn,s microfluidics screening and ... for novel small molecule therapeutics. ... work with FORMA Therapeutics to explore key pathways ... FORMA Therapeutics, decision to work with us is ...
(Date:7/29/2014)... July 29, 2014  ImmunoClin Corporation (IMCL) is ... treatment of infectious diseases as well as nutraceuticals. ... prevention of pathologies like cardiovascular disease, Alzheimer,s disease ... ImmunoClin Corporation will complete the strategic relocation of ... , a key center of North American ...
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready ... The Innovation Center @3401 , a collaborative effort of ... Center to help attract and nurture start-up businesses in ... , The Innovation Center @3401 (ic@3401), which ... is the new home of DreamIt Ventures and ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3
... Support Fund,s Goal of Finding a Cure for ... Animal Health and the National,Thoroughbred Racing Association (NTRA) ... the NTRA Charities - Barbaro Memorial Fund. The,partnership,s ... across the horse,industry and encourage further support of ...
... Novinski to Discuss Plans for Company in 2008 ... 31 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... Thursday, February 7, at 10:00 AM EST. President ... the company,s,emerging business strategy. Emisphere is a biopharmaceutical ...
... Board of Directors, SAN DIEGO, Jan. 31 ... therapeutics for the,treatment of Alzheimer,s disease, announced today ... A round of financing. The financing was led ... Partners. Additional,investors included AgeChem Venture Fund, and MC ...
Cached Biology Technology:Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund 2Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 2Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 3
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
(Date:7/29/2014)... preterm babies latest research from the University of ... the brains of many preterm children can perform almost as ... by the University,s Robinson Research Institute has found ... injury in early life, their cognitive abilities as a teenager ... However, the results of the study, published in this month,s ...
(Date:7/29/2014)... disease it affects 1 in 100,000 people characterized ... While its cause remains unknown, a new study by a ... of Bonn in Germany and other European institutions confirms for ... study, published on 6 July in Nature Genetics , ... When we swallow, a sphincter in the lower esophagus opens, ...
Breaking Biology News(10 mins):23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3Preterm children's brains can catch up years later 2Mysterious esophagus disease is autoimmune after all 2
... cousin of the bacterium that debilitated thousands of World War ... who had been on an international vacation. The woman, who ... typhoid fever, two infections that can occur in returning travelers. ... was infected with a new bacterium that had never before ...
... a single protein with an experimental drug prevented and ... mice that had been fed unhealthy diets and were ... article published online at Nature on June 6, 2007. ... chair of the Department of Genetics and Complex Diseases ...
... new clues to a very cold case: the disappearance of ... all Ice Age giants, according to a June 7th report ... , DNA lifted from the bones, teeth, and tusks of ... expansion after the last interglacial period. After the mammoths’ migration, ...
Cached Biology News:New bacterium discovered -- related to cause of trench fever 2New bacterium discovered -- related to cause of trench fever 3New bacterium discovered -- related to cause of trench fever 4In mice, drug protects against diabetes and atherosclerosis 2In mice, drug protects against diabetes and atherosclerosis 3In mice, drug protects against diabetes and atherosclerosis 4Ancient DNA traces the woolly mammoth's disappearance 2
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Request Info...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
Biology Products: